Drug retention rates in each JAKi-treated patients with and without high disease activity.
presentation
posted on 2024-07-11, 17:40 authored by Kenji Saito, Shuhei Yoshida, Honoka Ebina, Masayuki Miyata, Eiji Suzuki, Takashi Kanno, Yuya Sumichika, Haruki Matsumoto, Jumpei Temmoku, Yuya Fujita, Naoki Matsuoka, Tomoyuki Asano, Shuzo Sato, Kiyoshi MigitaThe starting point (0 years) is the date on which the observations began. DAS28-CRP: disease activity score 28 using C-reactive protein, JAKi: Janus kinase inhibitor; BARI: baricitinib; TOFA: tofacitinib; UPA: upadacitinib; No: number.
(PPTX)
History
Usage metrics
Categories
Keywords
kaplan &# 8211high disease activityeffective therapeutic agentscox regression modelrisk factors affectingretrospectively evaluated patientsoverall 184 patientsmulticenter cohort studyjanus kinase inhibitorsdrug retention ratesworld comparative studyjak1 inhibitors (<treatment discontinuation owingpatients receiving pan9 %), upadacitinib6 %), tofacitinibjaki treated patientsdrug retentionworld settingpredictive factorspatients treatedra receiving0 %),xlink ">significantly lowerrheumatoid arthritisrespectively ).reduced mainlymeier methodjakis (<higher incidencefirst jakidetermined usingclinical outcomesanalyzed usingadverse effects5 %)2 %).2 %)03 ).
Licence
Exports
RefWorks
BibTeX
Ref. manager
Endnote
DataCite
NLM
DC